Olanzapina Vir (Olanzapine)

Olanzapine, the active ingredient in Olanzapina Vir, is an atypical antipsychotic presented as a tablet for oral use. It treats schizophrenia and bipolar I disorder in adults and adolescents. GNH USA supplies Olanzapina Vir as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

GNH USA supplies Olanzapina Vir as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Olanzapine is used in the management of psychotic disorders, acting on dopamine and serotonin pathways to stabilize mood and thought processes.

- Schizophrenia: reduces positive and negative symptoms and helps prevent relapse. - Bipolar I disorder (manic episodes): controls acute mania and maintains mood stability. - Schizoaffective disorder: alleviates both psychotic and mood symptoms. - Maintenance therapy: supports long‑term symptom control in chronic psychotic conditions. - Adjunctive treatment: may be added to other antipsychotics when response is inadequate.

Olanzapine may cause a range of adverse reactions, from mild to serious.

Common Side Effects: - Weight gain - Sedation - Dry mouth - Constipation - Increased appetite - Dizziness

Serious or Rare Side Effects: - Neuroleptic malignant syndrome - Tardive dyskinesia - Severe hyperglycaemia - Agranulocytosis - Myocardial infarction - Seizures

Olanzapine should be used with careful clinical monitoring and patient education.

- Metabolic monitoring: regular assessment of weight, glucose and lipid profiles. - Cardiovascular assessment: monitor heart rate  and    ...   t   t  ...  ...  ewline  ...  -     ewline ...  ewline   ewline ... ... \

The       …  …  ewline   ....  ... 

     """"  "" "" "...